XNK Therapeutics to present at Redeye Regenerative Medicine/Cell Therapy event

2024-02-08

临床2期免疫疗法细胞疗法

HUDDINGE, Sweden, Feb. 8, 2024 /PRNewswire/ --

XNK Therapeutics AB ("XNK") today announced that Johan Liwing, CEO, will present the company at the Redeye Regenerative Medicine/Cell Therapy event on February 14.

XNK's presentation starts at 10:45 CET. The event will be broadcasted live starting at 09:00 CET and can be followed on Redeye's homepage.

XNK's presentation will be followed by a short Q&A session.

For more information, please contact:

Johan Liwing, CEO, XNK Therapeutics

Tel: +46 706 70 36 75

E-mail: [email protected]

About XNK Therapeutics AB

XNK Therapeutics is a clinical stage immunotherapy company focused on bringing new and more effective treatments to cancer patients. The company is at the forefront of autologous NK cell-based cell therapy development with a proprietary technology platform and a pipeline spanning both hematological malignancies and solid tumor indications. The most advanced product, evencaleucel, is in phase II studies in combination with the CD38 antibody isatuximab targeting multiple myeloma. Other programs include XNK02 in acute myeloid leukemia, currently in preclinical studies in collaboration with MD Anderson Cancer Center Cancer Center and the Karolinska University Hospital, XNK03 in bladder cancer, currently in preclinical studies in collaboration with the Karolinska University Hospital and XNK04 in liver cancer in collaboration with a global pharma company. XNK's efforts are supported by a dedicated team that includes world-renowned NK cell experts and an approved in-house GMP facility. XNK Therapeutics is headquartered in Stockholm, Sweden. For more info, please visit www.xnktherapeutics.com.

The following files are available for download:

SOURCE XNK Therapeutics AB

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构